Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation

Bone Marrow Transplantation volume 35, pages 583–586 (2005)Cite this article

Summary:

Caspofungin (CAS) is the first of a new class of antifungal agents, the echinocandins, that interfere with fungal cell wall synthesis by inhibition of glucan synthesis. Here, we report the results of 31 patients treated with CAS following allogeneic SCT. CAS was administered as a second-line agent to patients with invasive fungal infection (IFI) (n=15) or fever of unknown origin (n=16) who were recalcitrant to or intolerant of prior antifungal therapy. Unsuccessful first-line regimes included amphotericin B (n=17), liposomal amphotericin B (n=5), fluconazole (n=3), itraconazole (n=1), and voriconazole (n=2). All patients received concomitant immunosuppressive therapy for graft-versus-host disease. In 23 patients, cyclosporin A (CSA) and CAS were administered concurrently without any major side effects detected. Observed increases in GPT were not clinically significant. Normalization of serum creatinine and significant reductions in C-reactive protein were observed in response to CAS. Favorable outcome to CAS were documented in eight of 15 patients with IFI and in 15 of 16 patients with fever of unknown origin. CAS is a promising alternative in patients with IFI and fever of unknown origin in the setting of allogeneic SCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Groll AH, Walsh TJ . Potential new antifungal agents. Curr Opin Infect Dis 1997; 10: 449–454.

    Article  Google Scholar 

  2. Andriole VT . Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999; 44: 151–162.

    Article  CAS  Google Scholar 

  3. Wingard JR, Leather HL . Empiric antifungal therapy for the neutropenic patient. Oncology 2001, 351–361.

  4. Chiou CC, Groll AH, Walsh TJ . New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5: 120–235.

    Article  CAS  Google Scholar 

  5. Cannon JP, Garey KW, Danziger LH . A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001; 21: 1107–1114.

    Article  CAS  Google Scholar 

  6. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396.

    Article  CAS  Google Scholar 

  7. Graybill JR . The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001; 55: 633–638.

    CAS  PubMed  Google Scholar 

  8. Kurtz MB, Douglas CM . Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997; 35: 79–86.

    Article  CAS  Google Scholar 

  9. Stone EA, Fung HB, Kirschenbaum HL . Caspofungin: an echinocandin antifungal agent. Clin Ther 2002; 24: 351–359.

    Article  CAS  Google Scholar 

  10. Arathoon EG, Gotuzzo E, Noriega LM et al. A randomized, double-blind, multicenter study of caspofungin versus amphotericin in the treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46: 451–457.

    Article  CAS  Google Scholar 

  11. Sable CA, Nguyen B-YT, Chodakewitz JA, DiNubile MJ . Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis 2002; 4: 25–31.

    Article  CAS  Google Scholar 

  12. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529–1535.

    Article  CAS  Google Scholar 

  13. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294–299.

    Article  CAS  Google Scholar 

  14. Maertens J, Raad I, Petrikkos G et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungals: an analysis of 90 patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, San Diego, CA. Poster M-868, 2002.

  15. Cancidasâ„¢ [package insert]. Merck & Co., Inc.: Whitehouse Station, NJ, 2001.

  16. Mora-Duarte J, Robert Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029.

    Article  CAS  Google Scholar 

  17. Singh N . Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33: 1692–1696.

    Article  CAS  Google Scholar 

  18. Sobel JD . Practice guidelines for the treatment of fungal infections. Clin Infect Dis 2000; 30: 652.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany

    R Trenschel, M Ditschkowski, A H Elmaagacli, M Koldehoff, H Ottinger, N Steckel, M Hlinka, R Peceny & D W Beelen

  2. Institute of Medical Microbiology, University Hospital Essen, Essen, Germany

    P-M Rath & H Dermoumi

Authors
  1. R Trenschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Ditschkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A H Elmaagacli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Koldehoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Ottinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Steckel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Hlinka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Peceny
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P-M Rath
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Dermoumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D W Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Trenschel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trenschel, R., Ditschkowski, M., Elmaagacli, A. et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 35, 583–586 (2005). https://doi.org/10.1038/sj.bmt.1704859

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704859

Keywords

This article is cited by

Search

Advanced search

Quick links